{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:59:06Z","timestamp":1770699546986,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103264","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:59:26Z","timestamp":1770638366000},"source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis"],"prefix":"10.7759","author":[{"given":"Pooja","family":"Unnikrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirankanth","family":"Vudayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilipchandra","family":"Chintada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Khatija Begum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sriya","family":"Chalamalasetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Gullipalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths C","year":"2007","unstructured":"Griffiths C, Barker J. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: prevalence and pattern","volume":"76","author":"Dogra S","year":"2010","unstructured":"Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010, 76:595-601. 10.4103\/0378-6323.72443","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke WH","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015, 386:983-94. 10.1016\/S0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi R","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013, 133:377-85. 10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast A","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, et al.. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015, 29:2277-94. 10.1111\/jdv.13354","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12062","article-title":"Systemic methotrexate therapy for psoriasis: past, present and future","volume":"38","author":"Dogra S","year":"2013","unstructured":"Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013, 38:573-88. 10.1111\/ced.12062","journal-title":"Clin Exp Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren RB","year":"2016","unstructured":"Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016, 175:23-44. 10.1111\/bjd.14816","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian E","year":"2020","unstructured":"Sbidian E, Chaimani A, Afach S, et al.. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020, 1:CD011535. 10.1002\/14651858.CD011535.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes MA","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014, 32:227-55. 10.1146\/annurev-immunol-032713-120225","journal-title":"Annu Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010179","article-title":"Scanning the Immunopathogenesis of Psoriasis","volume":"19","author":"Chiricozzi A","year":"2018","unstructured":"Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018, 19:10.3390\/ijms19010179","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72 Suppl 2","author":"O'Shea JJ","year":"2013","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013, 72 Suppl 2:ii111-5. 10.1136\/annrheumdis-2012-202576","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb JE","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al.. Psoriasis. Nat Rev Dis Primers. 2016, 2:16082. 10.1038\/nrdp.2016.82","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al.. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020, 156:258-69. 10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman D","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al.. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017, 377:1525-36. 10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter A","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al.. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020, 82:1445-86. 10.1016\/j.jaad.2020.02.044","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle FO","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009, 361:496-509. 10.1056\/NEJMra0804595","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin CT","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017, 376:957-70. 10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3329\/jemc.v11i2.65193","article-title":"Efficacy and safety of tofacitinib vs methotrexate in patients with moderate to severe plaque psoriasis","volume":"11","author":"Khondker L","year":"2021","unstructured":"Khondker L. Efficacy and safety of tofacitinib vs methotrexate in patients with moderate to severe plaque psoriasis. J Enam Med Coll. 2021, 11:108-19. 10.3329\/jemc.v11i2.65193","journal-title":"J Enam Med Coll"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14695","article-title":"Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Kuo CM","year":"2018","unstructured":"Kuo CM, Tung TH, Wang SH, Chi CC. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2018, 32:355-62. 10.1111\/jdv.14695","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000250744","article-title":"Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359","volume":"158","author":"Fredriksson T","year":"1979","unstructured":"Fredriksson T, Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica. 1979, 158:60-4. 10.1159\/000250744","journal-title":"Dermatologica"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study","volume":"30","author":"Valenzuela F","year":"2016","unstructured":"Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016, 30:1753-9. 10.1111\/jdv.13702","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia S","year":"2022","unstructured":"Sarabia S, Ranjith B, Koppikar S, Wijeratne DT. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 2022, 6:71. 10.1186\/s41927-022-00287-7","journal-title":"BMC Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela F","year":"2018","unstructured":"Valenzuela F, Korman NJ, Bissonnette R, et al.. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018, 179:853-62. 10.1111\/bjd.16798","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo C","year":"2014","unstructured":"Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014, 28:192-203. 10.1111\/jdv.12081","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450337-a-comparative-study-of-oral-tofacitinib-and-oral-methotrexate-in-the-treatment-of-patients-with-moderate-to-severe-chronic-plaque-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:59:26Z","timestamp":1770638366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450337-a-comparative-study-of-oral-tofacitinib-and-oral-methotrexate-in-the-treatment-of-patients-with-moderate-to-severe-chronic-plaque-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.103264","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}